The antiproliferative effect of haloperidol might not be connected with action on dopamine D2 receptors, since haloperidol IC50 on cell proliferation is much higher than its inhibition of D2 dopamine receptors (~ 40 μM vs. ~30 nM) and there is no significant change in many dopamine D2 receptors in GBM, compared to normal tissue, as depicted in The Cancer Genome Atlas (TCGA). Here, DRD2 is linked to glioblastoma.